ECM-001 📄 Overview A SaMD platform integrating advanced imaging (e.g., elastography, MRI), liquid biopsy markers (circulating ECM proteins/metabolites), and clinical data to predict the onset, severity, and progression of fibrosis across organs (liver, lung, kidney). The platform provides personalized risk scores and supports early intervention strategies. Key technologies: 👤 Target users: 👍 Benefits Early and accurate diagnosis of fibrosis • Personalized prognosis and treatment pathways • Reduced progression to organ failure • Accelerated drug discovery and patient stratification for trials • Improved patient outcomes and quality of life Use bullets or new lines. 👎 Challenges Data heterogeneity and integration across different modalities • Rigorous clinical validation across diverse patient populations • Regulatory clearance for predictive algorithms as Class II/III SaMD • Interoperability with existing electronic health records (EHRs) 📋 Regulatory & Validation Likely Class II or III SaMD due to diagnostic/prognostic claims • Requires robust prospective validation studies • Emphasis on explainable AI and transparency of algorithm performance